Ketotifen
Histamine-1 Receptor Inhibitor — RESPIRATORY SYSTEM
Also known as: HC 20-511, ketotifen fumarate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ketotifen is an ofp drug in the Histamine-1 Receptor Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1999. Its mechanism of action is classified as Histamine H1 Receptor Antagonists. DrugCentral lists 27 molecular targets, including HRH1, HRH1 and HTR2A. Recorded indications include Allergic conjunctivitis.
- Approval status: ofp (first approved 1999 by the FDA).
- Drug class: Histamine-1 Receptor Inhibitor.
- Mechanism of action: Histamine H1 Receptor Antagonists.
- Molecular targets: HRH1, HRH1, HTR2A and CHRM5 (27 listed in DrugCentral).
- Indications: Allergic conjunctivitis.
- ATC code: R06AX17 (Other antihistamines for systemic use).
- Molecular formula: C19H19NOS; molecular weight 309.43 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Allergic conjunctivitis
Mechanism & targets
| Mechanism of action (MoA) | Histamine H1 Receptor Antagonists |
|---|---|
| Established pharmacologic class | Histamine-1 Receptor Inhibitor |
Molecular targets (27)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Histamine H1 receptor | HRH1 | unknown | Ki 9.51 |
| Histamine H1 receptor | HRH1 | antagonist | Ki 9.51 |
| 5-hydroxytryptamine receptor 2A | HTR2A | unknown | Ki 8.05 |
| Muscarinic acetylcholine receptor M5 | CHRM5 | unknown | Ki 7.73 |
| 5-hydroxytryptamine receptor 2B | HTR2B | unknown | Ki 7.54 |
| 5-hydroxytryptamine receptor 2C | HTR2C | unknown | Ki 7.08 |
| Muscarinic acetylcholine receptor M4 | CHRM4 | unknown | Ki 7.08 |
| Muscarinic acetylcholine receptor M1 | CHRM1 | unknown | Ki 7.02 |
| Muscarinic acetylcholine receptor M3 | CHRM3 | unknown | Ki 6.58 |
| Alpha-2B adrenergic receptor | ADRA2B | unknown | Ki 6.49 |
| 5-hydroxytryptamine receptor 3A | HTR3A | unknown | Ki 6.47 |
| Transmembrane protein 97 | TMEM97 | unknown | Ki 6.44 |
| 5-hydroxytryptamine receptor 7 | HTR7 | unknown | Ki 6.39 |
| D(1A) dopamine receptor | DRD1 | unknown | Ki 6.36 |
| Muscarinic acetylcholine receptor M2 | CHRM2 | unknown | Ki 6.36 |
| 5-hydroxytryptamine receptor 6 | HTR6 | unknown | Ki 6.28 |
| D(3) dopamine receptor | DRD3 | unknown | Ki 6.18 |
| Alpha-2A adrenergic receptor | ADRA2A | unknown | Ki 6.09 |
| 5-hydroxytryptamine receptor 1A | HTR1A | unknown | Ki 5.84 |
| D(2) dopamine receptor | DRD2 | unknown | Ki 5.76 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1999-07-02 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
R06AX17 | RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Other antihistamines for systemic use |
S01GX08 | SENSORY ORGANS › OPHTHALMOLOGICALS › DECONGESTANTS AND ANTIALLERGICS › Other antiallergics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Treatment failure | 1304.1 |
| Urticaria | 145.8 |
| Anaphylactic reaction | 138.2 |
| Mast cell activation syndrome | 137.6 |
| Perfume sensitivity | 131.2 |
| Mastocytosis | 117.7 |
| Pruritus | 80.6 |
| Mechanical urticaria | 72.1 |
| Muscle tension dysphonia | 68.3 |
| Angioedema | 67.6 |
| Dysphoria | 64.3 |
| Skin reaction | 59.8 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Ketotifen is on its molecule page.
| Molecular formula | C19H19NOS |
|---|---|
| Molecular weight | 309.43 g/mol |
| CAS number | 34580-13-7 |
| InChIKey | ZCVMWBYGMWKGHF-UHFFFAOYSA-N |
| PubChem CID | 3827 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ketotifen used for?
DrugCentral lists the following indications for Ketotifen: Allergic conjunctivitis.
How does Ketotifen work?
Ketotifen is classified as Histamine H1 Receptor Antagonists; its molecular targets in DrugCentral include HRH1, HRH1 (antagonist), HTR2A and CHRM5.
When was Ketotifen first approved?
Ketotifen was first approved by the FDA in 1999.
What drug class does Ketotifen belong to?
Ketotifen is in the Histamine-1 Receptor Inhibitor class.
What is the chemical formula of Ketotifen?
Ketotifen has the molecular formula C19H19NOS and a molecular weight of 309.43 g/mol.
Browse: all drugs starting with K · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1530 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1633 — compound record and bioactivity
- PubChem CID 3827 — chemical identifiers
- DrugBank DB00920 — drug record
- FDA UNII X49220T18G — substance identity
- DailyMed: FDA labels for Ketotifen — current prescribing information (label search)
- UniProt P35367 (HRH1) — target protein
- UniProt P28223 (HTR2A) — target protein
- UniProt P08912 (CHRM5) — target protein
- UniProt P41595 (HTR2B) — target protein
- UniProt P28335 (HTR2C) — target protein
- UniProt P08173 (CHRM4) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.